Kidney disease specialist Alebund Pharmaceuticals lists on HKEx Main Board
June 30, 2026 | 14:32
Alebund Pharmaceuticals (09637.HK) has made its debut on the Hong Kong Stock Exchange Main Board, deepening its commitment to kidney disease treatment and accelerating its path toward becoming a global leader in renal innovation.
Mobile Version